Drug Profile
ReN 009
Alternative Names: CTX cells; CTX DP; CTX-0E03 - ReNeuron - ReN009; ReN-009Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator ReNeuron
- Class Anti-ischaemics; Neural stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Huntington's disease
Highest Development Phases
- Preclinical Huntington's disease
- No development reported Peripheral ischaemia
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Peripheral-ischaemia(In the elderly) in United Kingdom (IM, Injection)
- 07 May 2020 ReN 009 is available for licensing as of 07 May 2020. http://www.reneuron.com/about-us/about-reneuron/
- 07 May 2020 Preclinical trials in Huntington's disease in United Kingdom (Intracerebral)